A technology evaluation of Annovera: a segesterone acetate and ethinyl estradiol vaginal ring used to prevent pregnancy for up to one year

Elizabeth A. Micks, Jeffrey T. Jensen

Research output: Contribution to journalArticle

Abstract

Introduction: The segesterone acetate and ethinyl estradiol contraceptive vaginal ring (SA/EE CVR) was FDA-approved in August 2018 and is now available in the U.S. The CVR is placed vaginally for 21 days followed by a 7-day ring-free interval, when withdrawal bleeding typically occurs. One ring can be used for up to a year (13 cycles). Areas covered: This review summarizes this novel method of contraception, including the delivery system and the hormonal components. We describe the potential market, how it is used, the pharmacokinetic properties of the device, and results of clinical trials including efficacy, bleeding profile, acceptability, and safety. Expert opinion: The SA/EE CVR represents the first long-lasting user-controlled hormonal contraceptive device. The bleeding pattern is highly favorable and consistent over the entire year and is associated with very low discontinuation. Efficacy and safety are similar to other methods of combined hormonal contraceptives. Unscheduled ring removals increase the risk of failure. Further studies are needed to evaluate continuous use of the ring for greater than 21 days, and potential non-contraceptive benefits of the ring such as reduced menstrual bleeding.

Original languageEnglish (US)
Pages (from-to)743-752
Number of pages10
JournalExpert Opinion on Drug Delivery
Volume17
Issue number6
DOIs
StatePublished - Jun 2 2020

Keywords

  • Annovera
  • combined hormonal contraception
  • vaginal ring contraception

ASJC Scopus subject areas

  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'A technology evaluation of Annovera: a segesterone acetate and ethinyl estradiol vaginal ring used to prevent pregnancy for up to one year'. Together they form a unique fingerprint.

  • Cite this